BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37965796)

  • 1. Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway.
    Li X; Chen G; Wang F; Guo X; Zhang R; Liu P; Dong L; Yu W; Wang H; Wang H; Yu J
    Clin Transl Med; 2023 Nov; 13(11):e1483. PubMed ID: 37965796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
    Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
    Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells.
    Hu N; Li Y; Zhao Y; Wang Q; You JC; Zhang XD; Ye LH
    Acta Pharmacol Sin; 2011 Jul; 32(7):921-9. PubMed ID: 21643005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
    Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
    Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
    Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM
    World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
    Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
    Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.
    Sánchez-Galán E; Gómez-Hernández A; Vidal C; Martín-Ventura JL; Blanco-Colio LM; Muñoz-García B; Ortega L; Egido J; Tuñón J
    Cardiovasc Res; 2009 Jan; 81(1):216-25. PubMed ID: 18852255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
    Zhao Z; Qin J; Qian Y; Huang C; Liu X; Wang N; Li L; Chao Y; Tan B; Zhang N; Qian M; Li D; Liu M; Du B
    J Hematol Oncol; 2024 Feb; 17(1):9. PubMed ID: 38402237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
    Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
    Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.
    Koundouros N; Karali E; Tripp A; Valle A; Inglese P; Perry NJS; Magee DJ; Anjomani Virmouni S; Elder GA; Tyson AL; Dória ML; van Weverwijk A; Soares RF; Isacke CM; Nicholson JK; Glen RC; Takats Z; Poulogiannis G
    Cell; 2020 Jun; 181(7):1596-1611.e27. PubMed ID: 32559461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
    Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
    Jiang W; Ouyang X; Li C; Long Y; Chen W; Ji Z; Shen X; Xiang L; Yang H
    Immunology; 2023 Nov; 170(3):419-438. PubMed ID: 37469254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
    Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
    Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway.
    Chen J; Tang Y; Qin D; Yu X; Tong H; Tang C; Tang Z
    J Transl Med; 2023 Dec; 21(1):923. PubMed ID: 38124204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.